Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Nebibe Varol"'
Autor:
Nicolas Girard, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, Mohammad A. Chaudhary, Sarah Goring, Greta Lozano-Ortega, Mia Tran, Nebibe Varol, Nathalie Waser, Jay M. Lee, Jonathan Spicer
Publikováno v:
Cancers, Vol 16, Iss 13, p 2492 (2024)
Background: This study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC) patients. Me
Externí odkaz:
https://doaj.org/article/6e19752816b0486883be861758bb2cad
Autor:
Hollie Bailey, Adam Lee, Laura Eccles, Yong Yuan, Helen Burlison, Cameron Forshaw, Nebibe Varol
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-20 (2023)
Abstract Background The landscape of non-small cell lung cancer (NSCLC) therapy is rapidly changing. This analysis aimed to understand patient characteristics, diagnosis and treatment patterns in patients with metastatic NSCLC (mNSCLC) without EGFR a
Externí odkaz:
https://doaj.org/article/f8482c80caec44f49f6bf2dacb909e26
Publikováno v:
Value in Health. 17:A260
Publikováno v:
In Value in Health May 2014 17(3):A260-A260
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100648- (2022)
Background: The advent of immunotherapies (I-O) and targeted therapies has transformed the treatment landscape in advanced non-small cell lung cancer (NSCLC). However, adoption of new treatment guidelines and evolving treatment patterns in clinical p
Externí odkaz:
https://doaj.org/article/33afb381bc5b45f399a840144ff3c4b8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maria, Polyzoi, Hera, Sandhu, Johan, Maervoet, Yong, Yuan, Mohammad A, Chaudhary, Nebibe, Varol, Adam, Lee, Peter, Dale, Cheryl, Jones, Solomon J, Lubinga, John R, Penrod
Publikováno v:
Journal of Medical Economics. 25:660-668
This economic analysis evaluated the cost-effectiveness of nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of platinum-doublet chemotherapy (PDC) compared with four cycles of PDC as first-line treatment for patients with advanced NSCLC in the
Autor:
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, Adam Lee, Yong Yuan, Laura Eccles, Phuong Tran, John R. Penrod
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
The study objective was to estimate the relationship between objective response and survival-based endpoints by drug class, in first-line advanced non-small cell lung cancer (aNSCLC).A systematic literature review identified randomized controlled tri
Publikováno v:
Value in Health. (3):A260
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 135
Objectives Platinum-based chemotherapy is the mainstay of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of car